Novartis Surges to 279th in Trading Volume with 3.03 Billion Turnover Amid FDA Approval for Rare Kidney Disease Treatment

On April 2, 2025, Novartis (NVS) saw a significant increase in trading volume, with a turnover of 3.03 billion, marking a 40.35% rise from the previous day. This surge placed Novartis at the 279th position in terms of trading volume for the day. The stock price of Novartis also rose by 1.06%.

Novartis has recently received its third FDA approval for its oral medication Fabhalta (iptacopan), making it the first and only treatment approved for C3 glomerulopathy (C3G). This approval is a significant milestone for Novartis, as it expands the therapeutic options available for patients suffering from this rare and severe kidney disease. The approval was based on positive clinical trial data demonstrating the drug's efficacy and safety in reducing proteinuria, a key indicator of kidney function.

Novartis is also evaluating Fabhalta for a broader range of rare kidney diseases, including atypical hemolytic uremic syndrome, immune complex membranoproliferative glomerulonephritis, and lupus nephritis. This ongoing research and development effort underscores Novartis' commitment to advancing treatments for rare and severe kidney diseases, positioning the company as a leader in this therapeutic area.